Foundation Medicine (United States)

Recent papers from Foundation Medicine (United States)

1. Tumor analysis identifies Israeli founder pathogenic variation carriersnpj Genomic Medicine · 2026
2. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialThe Lancet · 2016
3. Prevalence of High Tumor Mutational Burden Among Pediatric Patients With Solid TumorsPediatric Hematology and Oncology · 2026
4. Prospective Evaluation of Circulating Tumor DNA in Metastatic Hormone-Sensitive Prostate CancerJCO Precision Oncology · 2026
5. Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancerEuropean Journal of Cancer · 2026
6. Associations between early changes in circulating tumor DNA (ctDNA) and outcomes across randomized trials: Insights from the ctMoniTR projectThe Journal of Liquid Biopsy · 2026
7. Perspectives From an Expert-Guided Discussion on Maximizing the Research Potential of Small Biopsy TissueJCO Precision Oncology · 2026
8. Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World OutcomesJCO Precision Oncology · 2026
9. Turnaround Time of Comprehensive Genomic Profiling in Lung Cancer and Other Solid TumorsJCO Oncology Practice · 2026
10. Comparison between molecular and histological IDH-wild-type glioblastoma and extensive subgroup analysis of IDH-wild-type astrocytic tumors without genomic glioblastoma-defining alterationsJournal of Neuro-Oncology · 2026
11. From Sequencing to Treatment: Operational Challenges in Translating Precision Oncology Into Clinical PracticeAmerican Society of Clinical Oncology Educational Book · 2026
12. Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 TrialJournal of Clinical Oncology · 2026
13. Clinical utility of DNA and RNA next-generation sequencing (NGS) for accurate diagnosis (Dx) and sub-classification of bone and soft tissue tumors (BST).Journal of Clinical Oncology · 2026
14. Impact of concurrent tissue (TBx) and liquid (LBx)–based comprehensive genomic profiling (CGP) on biomarker detection and first-line (1L) treatment in metastatic CRC (mCRC).Journal of Clinical Oncology · 2026
15. Frameworks for improving comprehensive biomarker testing in NSCLC: A multi-stakeholder consensus.Journal of Clinical Oncology · 2026
16. Characterization of genomic alterations between local breast cancers and cutaneous metastases.Journal of Clinical Oncology · 2026
17. Impact of molecular profile on switch maintenance to paclitaxel plus ramucirumab (PTX-RAM) versus continuation of first-line fluoropyrimidine and oxaliplatin (FOX) chemotherapy (ChT) in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: An exploratory endpoint of the ARMANI phase 3 randomized trial.Journal of Clinical Oncology · 2026
18. Inferring optimal detection of homozygous loss (homozygous deletion) in head and neck cancer: Associations with HPV status, primary disease site, and clinical outcomes.Journal of Clinical Oncology · 2026
19. Fast-TRACKing precision oncology for rare cancers: A national decentralized trial offering comprehensive genomic profiling and a molecular tumor board.Journal of Clinical Oncology · 2026
20. Neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer: Final results and biomarker analyses of the SURE-01 trial.Journal of Clinical Oncology · 2026